Travere Drug Patent Portfolio

Travere owns 1 orange book drug protected by 1 US patent Given below is the list of Travere's drug patents along with their expiration dates.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US9993461 Method for treating disorders associated with glomerular function 29 Mar, 2030
Active


Given below is the list of recent legal activities going on the following drug patents of Travere.

Activity Date Patent Number
Patent litigations
Second letter to regulating agency to determine regulatory review period 08 May, 2024 US9993461
Letter from FDA or Dept of Agriculture re PTE application 30 Jan, 2024 US9993461
Initial letter Re: PTE Application to regulating agency 17 Nov, 2023 US9993461
Resp. to req. for info. sent under 37 CFR 1.750 12 Sep, 2023 US9993461
Requirement for information sent under 37 CFR 1.750 04 Aug, 2023 US9993461
Patent Term Extension Application under 35 USC 156 Filed 14 Apr, 2023 US9993461
Payment of Maintenance Fee, 4th Yr, Small Entity 13 Dec, 2021 US9993461
Patent Issue Date Used in PTA Calculation 12 Jun, 2018 US9993461
Recordation of Patent Grant Mailed 12 Jun, 2018 US9993461
Email Notification 24 May, 2018 US9993461
Issue Notification Mailed 23 May, 2018 US9993461
Dispatch to FDC 14 May, 2018 US9993461
Printer Rush- No mailing 23 Apr, 2018 US9993461
Pubs Case Remand to TC 16 Apr, 2018 US9993461
Printer Rush- No mailing 04 Apr, 2018 US9993461


Travere Drug Patents' Oppositions Filed in EPO

Travere drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Nov 23, 2020, by Pajaro Limited. This opposition was filed on patent number EP17157697A. Click below to reveal the latest opposition data.


Application Filing Date Opposition Party Legal Status
Patent litigations
EP17157697A Nov, 2020 Pajaro Limited Granted and Under Opposition


Travere's Family Patents

Travere drugs have patent protection in a total of 14 countries. It's US patent count contributes only to 25.0% of its total global patent coverage. 1 country has all of their patents expired or invalidated which has opened up potential generic launch opportunities in this particular country. Click below to unlock the full patent family tree.

Family Patents



Travere Drug List

Given below is the complete list of Travere's drugs and the patents protecting them.


1. Filspari

Filspari is protected by 1 patent, which is still active. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US9993461 Method for treating disorders associated with glomerular function 29 Mar, 2030
(5 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Filspari's drug page


Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List